MARIETTA, Ohio--(BUSINESS WIRE)--ProtoKinetix, Incorporated (www.protokinetix.com) (the "Company" or "ProtoKinetix") (OTCQB:PKTX) today announced reaching the midpoint of a Phase-1 first-in-human ...
– TransCon CNP demonstrated AGV superior to placebo with LS mean treatment difference of 1.49 cm/year at Week 52 (p<0.0001) – For children aged 5-11 years TransCon CNP demonstrated a change from ...
Tolerability profile supported by dosimetry and low-grade non-hematologic events. Lesion dosimetry indicates no difference in absorbed dose profile across cohorts. No adverse drug-drug interactions ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results